Should you buy ABEO stock?

Last updated:

Based on market data through , StockInvest.us rates Abeona Therapeutics Inc. (ABEO) as a Strong Buy Candidate with a technical score of 5.68 on its -10 to +10 scale. This is an upgrade from Buy in the previous daily evaluation.

  • Buy signal since
  • Price since signal Up 16.21%
  • 3-month trend forecast Up 24.15%
  • Strong Buy Candidate 5.68
AI Analysis AI Analysis of ABEO AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add ABEO to Watchlist?
Some Reasons Why To Add ABEO:
  • Strong return on equity of 41.4%
  • Bullish trend confirmed on both short and long timeframes
  • Highly efficient cash conversion (110% FCF/OCF ratio)
PDF

Stronger technical forecast for Abeona Therapeutics Inc. stock price after Friday trading
(Market data through Aug 07, 2026)

Buy or Hold candidate since Jul 29, 2026 Gain 16.21%

The Abeona Therapeutics Inc. stock price gained 4.93% on the last trading day (Friday, 7th Aug 2026), rising from $6.90 to $7.24. During the last trading day the stock fluctuated 5.19% from a day low at $6.94 to a day high of $7.30. The price has risen in 6 of the last 10 days and is up by 19.67% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 568 thousand more shares were traded than the day before. In total, 1 million shares were bought and sold for approximately $10.11 million.

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 24.15% during the next 3 months and, with a 90% probability hold a price between $7.71 and $9.56 at the end of this 3-month period.

ABEO Signals & Forecast

The Abeona Therapeutics Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $6.72 and $6.42. A breakdown below any of these levels will issue sell signals. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Wednesday, July 15, 2026, and so far it has fallen -0.686%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Abeona Therapeutics Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $6.05 and $5.65. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Abeona Therapeutics Inc. finds support just below today's level at $6.05. If this is broken, then the next support from accumulated volume will be at $5.65 and $5.61.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.360 between high and low, or 5.19%. For the last week, the stock has had daily average volatility of 4.45%.

Our recommended stop-loss: $6.97 (-3.68%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 17 days ago.)

Trading Expectations (ABEO) For The Upcoming Trading Day Of Monday 10th

For the upcoming trading day on Monday, 10th we expect Abeona Therapeutics Inc. to open at $7.16, and during the day (based on 14 day Average True Range), to move between $7.08 and $7.40, which gives a possible trading interval of +/-$0.325 (+/-4.59%) up or down from last closing price. If Abeona Therapeutics Inc. takes out the full calculated possible swing range there will be an estimated 4.59% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $7.29 (0.69%) than the support at $6.05 (16.44%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Earnings coming up

Abeona Therapeutics Inc. will release earnings BMO on Thursday, August 13, 2026.The consensus among the analysts for the expected earnings (EPS) is -$0.230. We will update the financials statements for Abeona Therapeutics Inc., that can be found here as soon as the records are public. Our systems has calculated a possible swing of +/- 11.55% in the first trading day after earnings release.

Is Abeona Therapeutics Inc. stock A Buy?

Abeona Therapeutics Inc. holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months. We have upgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Strong Buy candidate.

Current score: 5.683 Strong Buy Candidate Upgraded

Predicted Fair Opening Price

Predicted fair opening price on August 10, 2026 - $7.16 ( 1.10%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

ABEO Performance

Trading levels for ABEO

StockInvest.us
Full Access. No Commitment. Up to 14 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 7.52 3.87%
R2 7.38 1.97%
R1 7.30 0.794%
Price 7.24
S1 7.02 -3.00%
S2 6.94 -4.18%
S3 6.80 -6.08%

Accumulated Volume Support & Resistance Levels

Level Price
R3 0 -
R2 0 -
R1 7.29 0.691%
Price 7.24
S1 6.05 -16.44%
S2 5.65 -21.96%
S3 5.61 -22.51%

ABEO Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Mar 31, 2000 Mar 31, 2000 Mar 31, 2000 $3,706.25 8.55%

FAQ

What is the symbol for Abeona Therapeutics Inc. Stock and on which exchange is it traded?
The symbol for Abeona Therapeutics Inc. is ABEO and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Abeona Therapeutics Inc. Stock?
Based on market data through Aug 07, 2026, StockInvest.us rates Abeona Therapeutics Inc. (ABEO) as a Strong Buy Candidate with a technical score of 5.68 on its -10 to +10 scale. This is an upgrade from Buy in the previous daily evaluation. Since the Buy signal began on Jul 29, 2026, the price has risen 16.21%. The current 3-month trend forecast projects a rise of 24.15%.

How to buy Abeona Therapeutics Inc. Stock?
Abeona Therapeutics Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Abeona Therapeutics Inc. Stock.

What's the current price of Abeona Therapeutics Inc. Stock?
As of the end of day on the Aug 07, 2026, the price of an Abeona Therapeutics Inc. (ABEO) share was $7.24.

What is the 52-week high and low for Abeona Therapeutics Inc. Stock?
The 52-week high for Abeona Therapeutics Inc. Stock is $7.54 and the 52-week low is $4.00.

What is the market capitalization of Abeona Therapeutics Inc. Stock?
As of the Aug 07, 2026, the market capitalization of Abeona Therapeutics Inc. is 412.645M.

When is the next earnings date for Abeona Therapeutics Inc.?
The upcoming earnings date for Abeona Therapeutics Inc. is Aug 13, 2026.
Click to get the best stock tips daily for free!
ABOUT ABEONA THERAPEUTICS INC.
Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;...
GOLDEN STAR
Ticker Change Signal Date
MHO
$150.54
0.96% Aug 05
JEF
$55.71
1.63% Aug 04
FCX
$62.63
11.16% Jul 31
BIIB
$202.19
2.84% Jul 24
S
SW
$43.71
10.46% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE